SunBioInc Valuation
Is A067370 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A067370 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A067370 (₩6570) is trading above our estimate of fair value (₩1892.85)
Significantly Below Fair Value: A067370 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A067370?
Key metric: As A067370 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is A067370's PB Ratio? | |
|---|---|
| PB Ratio | n/a |
| Book | ₩4.54b |
| Market Cap | ₩78.93b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does A067370's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.7x | ||
A950200 Psomagen | 2.6x | n/a | ₩82.1b |
A185490 EyeGene | 1.4x | n/a | ₩76.5b |
A196300 Anygen | 10.9x | n/a | ₩84.6b |
A127120 DNA Link | 3.9x | n/a | ₩91.5b |
A067370 SunBioInc | n/a | n/a | ₩80.9b |
Price-To-Book vs Peers: Insufficient data to calculate A067370's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Book Ratio vs Industry
How does A067370's PB Ratio compare vs other companies in the KR Biotechs Industry?
| 4 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 4 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: Insufficient data to calculate A067370's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is A067370's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | n/a |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate A067370's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
J2KBIO
₩54.5b
A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.
A420570
₩9,830.00
7D
6.0%
1Y
n/a
Hugel
₩3.0t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩268,000.00
7D
-3.4%
1Y
75.9%
Dong-A ST
₩544.1b
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
A170900
₩62,300.00
7D
-2.0%
1Y
8.6%